Vertex Pharmaceuticals experimental triple combination cystic fibrosis (CF) treatment met all late-stage study goals when tested in patients aged 12 years and older, the company said on Monday.
https://finance.yahoo.com/news/vertexs-triple-combination-cf-drug-211325860.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.